Cervical Squamous Cell Carcinoma Clinical Trial
Official title:
A Perspective, Multi-center, Single Arm Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma
Status | Not yet recruiting |
Enrollment | 125 |
Est. completion date | December 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: 1. Age=65 years old 2. Histologically confirmed primary cervical squamous cell carcinoma in stage IB3-IVA (FIGO 2018) 3. At least one measurable lesion according to RECIST 1.1 guideline 4. Patients are intolerant to or refuse chemotherapy. 5. No serious hematopoietic dysfunction, nor abnormal heart, lung, liver and kidney function, nor immunity deficiency. And the results of lab test meet the following criteria: Hemoglobin =90g/L Absolute count of neutrophils=2×109/L orwhite blood cell count=4.0×109/L; Platelet count=100×109/L; AST=2.5×ULN ALT=2.5×ULN TBIL=1.5×ULN; Serum creatinine=1.5×ULN or CrCl> 60 mL/min(according toCockcroft-Gault): Serum creatinine=1.5×ULN Female CrCl=(140-Age)×Weight(kg)×0.85 / (72×Scr mg/dl) 6. ECOG score 0-2 7. Expectancy of life is at least 3 months. 8. Eligible for pelvic MRI examination. 9. The patients voluntarily received nimotuzumab combined with radiotherapy. 10. Patients can comply with the protocol and are willing to sign informed consent. Exclusion Criteria: 1. Patients who have received treatment for cervical cancer, including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy 2. Patients who have bilateral ureteral obstruction, who cannot be placed ureteral stents or perform pyelostomy. 3. Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or with fistula risk. .4)Patients infected with HIV. 5)Active hepatitis B (HBV DNA quantitative test results exceed the detection threshold), or HCV infection (HCV RNA quantitative test results exceed the detection threshold) 6)Patients with severe underlying disease that makes it possible to safely receive the treatment. And the severe underlying disease include but not limited to active infections requiring systemic medication, decompensated heart failure (NYHA grade III and IV), unstable angina pectoris, and acute myocardial infarction occurred within the first 3 months of enrollment. 7)Patients with a history of prior malignancy other than cured basal cell carcinoma of the skin. 8)Patients with Crohn's disease and ulcerative colitis. 9)Patients are allergic to Nimotuzumab or its compounds. 10)Patients with neurological or psychiatric abnormalities that affect cognitive ability. 11)Intracavitary brachytherapy cannot be performed that was assessed by the investigator. 12)Other factors were assessed by investigators to be unsuitable to this study. |
Country | Name | City | State |
---|---|---|---|
China | Peking University 3rd Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3-year disease-free survival(DFS) | The rate of patient without disease in 3 years after treatment | up to 3 years | |
Secondary | Complete response rate(CRR) | The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression | 3 months later after treatment | |
Secondary | Objective response rate(ORR) | The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment | 3 months later treatment | |
Secondary | 3-year overall survival(OS) | The rate of patient alive in 3 years after treatment | up to 3 years | |
Secondary | The change of tumor related markers | the correlation of the value of SCC,Cyfra 21-1 and therapeutic effect [The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment] | up to 3 years | |
Secondary | The change of cervical tumor | the change of the volume of the cervical tumor at diagnosis and before brachytherapy | At diagnosis and before brachytherapy | |
Secondary | QUALITY OF LIFE(QoL) | Quality of life assessed by EORTC QLQ-CX 24 [EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items] | up to 3 years | |
Secondary | SAFETY | Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0 | up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05013268 -
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
|
Phase 1 | |
Completed |
NCT02562729 -
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
|
Phase 2 | |
Completed |
NCT00054444 -
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
Phase 1 | |
Completed |
NCT00416455 -
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT01759355 -
Hybrid PET/MR in the Therapy of Cervical Cancer
|
||
Completed |
NCT00068549 -
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03983954 -
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00559377 -
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
|
Phase 2 | |
Completed |
NCT00309959 -
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05613283 -
Primary Cervical Cancer Screening by Self-sampling HPV Test
|
||
Completed |
NCT00064077 -
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
|
Phase 3 | |
Active, not recruiting |
NCT02466971 -
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
|
Phase 3 | |
Completed |
NCT02164461 -
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
|
Phase 1 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00031993 -
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
|
Phase 2 | |
Active, not recruiting |
NCT01649089 -
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
|
N/A | |
Completed |
NCT00499031 -
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00070317 -
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
|
N/A | |
Active, not recruiting |
NCT03738228 -
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
|
Phase 1 |